Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

Journal of the American College of Cardiology

Volumn 68, Issue 3, 2016, Pages 241-248

  Desai, Akshay S ^a   Claggett, Brian L ^a   Packer, Milton ^b   Zile, Michael R ^c   Rouleau, Jean L ^d   Swedberg, Karl ^e,f   Shi, Victor ^g   Lefkowitz, Martin ^g   Starling, Randall ^h   Teerlink, John ⁱ   McMurray, John J V ^j   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

hospitalization; neprilysin; readmission; sacubitril valsartan

Indexed keywords

ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; HEART STROKE VOLUME; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROGNOSIS; TIME FACTOR; TRENDS;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; TETRAZOLES; TIME FACTORS;

EID: 84979929924     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.04.047     Document Type: Article

References (20)

1. 1 Heidenreich, P.A., Sahay, A., Kapoor, J.R., Pham, M.X., Massie, B., Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006. J Am Coll Cardiol 56 (2010), 362–368.
2. 2 Chen, J., Ross, J.S., Carlson, M.D., et al. Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. Am J Med 125 (2012), 100.e1–100.e9.
3. 3 Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
4. 4 Madigan, E.A., Gordon, N.H., Fortinsky, R.H., et al. Rehospitalization in a national population of home health care patients with heart failure. Health Serv Res 47 (2012), 2316–2338.
5. 5 Van Walraven, C., Bennett, C., Jennings, A., et al. Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ 183 (2011), E391–E402.
6. 6 McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
7. 7 Packer, M., McMurray, J.J.V., Desai, A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
8. 8 McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
9. 9 Bello, N.A., Claggett, B., Desai, A.S., et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail 7 (2014), 590–595.
10. 10 Setoguchi, S., Stevenson, L.W., Schneeweiss, S., Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154 (2007), 260–266.
11. 11 Solomon, S.D., Dobson, J., Pocock, S., et al., for the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007), 1482–1487.
12. 12 Chun, S., Tu, J.V., Wijeysundera, H.C., et al. Lifetime analysis of hospitalizations and survival of patients newly-admitted with heart failure. Circ Heart Fail 5 (2012), 414–421.
13. 13 Albert, N.M., Barnason, S., Deswal, A., et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail 8 (2015), 384–409.
14. 14 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
15. 15 Ahmed, A., Bourge, R.C., Fonarow, G.C., et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med 127 (2014), 61–70.
16. 16 Heidenreich, P.A., Hernandez, A.F., Yancy, C.W., et al. Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes 5 (2012), 37–43.
17. 17 Bhatia, V., Bajaj, N.S., Sanam, K., et al. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure. Am J Med 128 (2015), 715–721.
18. 18 Anand, I.S., Win, S., Rector, T.S., Cohn, J.N., Taylor, A.L., Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. Circ Heart Fail 7 (2014), 759–765.
19. 19 Lala, A., McNulty, S.E., Mentz, R.J., et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF). Circ Heart Fail 8 (2014), 741–748.
20. 20 Adamson, P.B., Abraham, W.T., Bauman, J., Yadav, J., Impact of wireless pulmonary artery pressure monitoring on heart failure hospitalizations and all-cause 30-day readmissions in Medicare-eligible patients with NYHA class III heart failure: results from the CHAMPION Trial. Circulation, 130, 2014, A166744.